Changing epidemiological aspects of candidemia and their clinical and therapeutic implications;Los aspectos epidemiológicos cambiantes de la candidemia y sus implicaciones clinicoterapéuticas

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 24, Issue SUPPL.1, 2006, Pages 36-45

  Salavert Lletí, Miguel ^a   Jarque Ramos, Isidro ^a   Pemán García, Javier ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Antifungal prophylaxis; Candida krusei; Candidemia; Fluconazole; Invasive candidiasis

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; MYCOGRAB; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

BACTERIUM ISOLATION; BLOOD FLOW; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDEMIA; CANDIDIASIS; CLINICAL TRIAL; HUMAN; INFECTION PREVENTION; REVIEW;

CANDIDEMIA; HUMANS; RISK FACTORS;

EID: 34548800232     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13094277     Document Type: Review

References (55)

1. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999;29:239-44.
2. Rentz A, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis. 1998;27:781-8.
3. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003;37:1172-7.
4. Sota M, Ezpeleta C, Cisterna R. Descripción de 165 episodios de funguemia de un estudio multicéntrico. Rev Iberoam Micol. 1999;16:30-5.
5. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36:1103-10.
6. Cantón E, Viudes A, Pemán J. Infección sistémica nosocomial por levaduras. Rev Iberoam Micol. 2001;18:51-5.
7. Saiman L, Ludington E, Pfaller M, Rangel-Frausto S, Wiblin RT, Dawson J, et al. Risk factors for candidemia in neonatal intensive care unit patients. Pediatr Infect Dis J. 2000;19:319-24.
8. Marr KA, Seidel K, Slavin MA, Borden RA, Schoch HG, Flowers ME, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood. 2000;96:2055-61.
9. Jarque I, Saavedra S, Martín G, Pemán J, Pérez-Bellés C. Sanz MA. Delay of onset of candidemia and emergence of Candida krusei fungemia in haematological patients receiving prophylactic fluconazole. Haematologica. 2000;85:441-2.
10. Marr KA, Seidel K, White TC, Borden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after adoption of prophylactic fluconazole. J Infect Dis. 2000;181:309-16.
11. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis. 2001;33:177-86.
12. Leleu G, Aegerter P, Guidet B. Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care. 2002;17:168-75.
13. León C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Álvarez-Lerma F, et al. A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med. 2006;34:730-7.
14. Mayhall CG. The epidemiology of burn wound infections: then and now. Clin Infect Dis. 2003;37:543-50.
15. Grohskopf LA, Sinkowitz-Cochran RL, Garrett DO, Sohn AH, Levine GL, Siegel JD, et al. A national point-prevalence survey of pediatric intensive care unit-acquired infections in the United States. J Pediatr. 2002;140:432-8.
16. Krcmery V, Laho L, Huttova M, Ondrusova A, Kralinsky K, Pevalova L, et al. Aetiology, antifungal susceptibility, risk factors and outcome in 201 fungaemic children: data from a 12-year prospective national study from Slovakia. J Med Microbiol. 2002;51:110-6.
17. Kaufman D, Boyle R, Hazen KC, Patrie JT, Robinson M, Donowitz LG. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med. 2001;345:1660-6.
18. Abi-Said D, Anaissie E, Uzum O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis. 1997;24:1122-8.
19. Krcmery V, Barnes AJ. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect. 2002;50:243-60.
20. Girmenia C, Martino P. Fluconazole and the changing epidemiology of candidemia. Clin Infect Dis. 1998;27:232-3.
21. Tortorano AM, Pemán J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, et al. Epidemiology of candidemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis. 2004;23:317-22.
22. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Kart JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991;325:1274-7.
23. Pemán J, Cantón E, Gobernado M. Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis. 2005:24:23-30.
24. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Saral R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother. 1993;37:1847-9.
25. Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect 2002;50:56-65.
26. Abbas J, Bodey GP, Hanna HA, Mardani M, Girgawy E, Abi-Said D, et al. Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med. 2000;160:2659-64.
27. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, et al. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis. 2004;38:311-20.
28. Arendrup MC, Fuursted K, Gahrn-Hansen B, Jensen IM, Knudsen JD, Lundgren B, et al. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol. 2005;43:4434-40.
29. Almirante B, Rodriguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, et al. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol. 2005;43:1829-35.
30. Viudes A, Pemán J, Cantón E, Salavert M, Úbeda P, López-Ribot JL, et al. Two cases of fungemia due to Candida lusitaniae and a literature review. Eur J Clin Microbiol Infect Dis. 2002;21:294-9.
31. Muñoz P, Sánchez-Somolinos, Alcalá L, Rodríguez-Creixems, Peláez T, Bouza E. Candida krusei fungaemia: antifungal susceptibility and clinical presentation o fan uncommon entity during 15 years in a single general hospital. J Antimicrob Chemother. 2005;55: 188-93.
32. Uzum O, Ascioglu S, Anaissie EJ, Rex JH. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis. 2001;32:1713-7.
33. Nucci M, Colombo AL. Risk factors for breakthrough candidemia. Eur J Clin Microbiol Infect Dis. 2002;21:209-11.
34. Pagano L, Mele L, Fianchi L, Melillo L, Martino B, D'Antonio D, et al. Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. Haematologica. 2002;87:535-41.
35. Clancy CJ, Barchiesi F, Falconi DiFrancesco L, Morris AJ, Snydman DR, Yu VL, et al. Clinical manifestations and molecular epidemiology of late recurrent candidemia, and implications for management. Eur J Clin Microbiol Infect Dis. 2000;19:585-92.
36. Nucci M, Anaissie EJ. Should vascular catheters be removed from all patients with candidemia? An evidence-based review. Clin Infect Dis. 2002;34:591-9.
37. Gadea I, Cuenca-Estrella M, y Grupos MICOMED y GESITRA de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Recomendaciones para el diagnóstico micológico y estudios de sensibilidad a los antifúngicos. Enferm Infecc Microbiol Clin. 2004;22:32-9.
38. García-Ruiz JC, Arilla MC, Regúlez P, Quindos G, Álvarez A, Pontón J. Detection of antibodies to Candida albicans germ tubes for diagnosis and therapeutic monitoring of invasive candidiasis in patients with hematologic malignancies. J Clin Microbiol. 1997;35:3284-7.
39. Moragues MD, Ortiz N, Iruretagoyena JR, García-Ruiz JC, Amutio E, Rojas A, et al. Evaluation of a new commercial test (Candida albicans IFA IgG) for the serodiagnosis of invasive candidiasis. Enferm Infecc Microbiol Clin. 2004;22:83-8.
40. Martino R, Salavert M, Parody R, Tomas JF, De la Cámara R, Vázquez L, et al. Blastoschizomyces capitatus infection in patients with leukemia: report of 26 cases. Clin Infect Dis. 2004;38:335-41.
41. Peláez T, García-Arias V, Alcalá L, Fernández-Chico A, Blázquez A, Guinea JV, et al. Epidemiology and in vitro antifungal susceptibilities of Trichosporon spp.: an overview of a 15-year period. 43rd ICAAC, September 2003, p. 468. Abstract M-1222.
42. Muñoz P, Bouza E, Cuenca-Estrella M, Eiros JM, Perez MJ, Sanchez-Somolinos M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis. 2005;40:1625-34.
43. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38:161-89.
44. Gavaldá J, Ruiz I. Recomendaciones para el tratamiento de la infección fúngica invasiva. Infección fúngica invasiva por Candida spp. Enferm Infecc Microbiol Clin. 2003;21:498-508.
45. Büchner T, Fegeler W, Bernhardt H, Brockmeyer N, Duswald KH, Herrmann M, et al. Treatment of severe Candida infections in high-risk patients in Germany: consensus formed by a panel of interdisciplinary investigators. Eur J Clin Microbiol Infect Dis. 2002;21:337-52.
46. Pachón J, Cisneros JM, Collado-Romacho AR, Lomas-Cabezas JM, Lozano de León-Naranjo F, Parra-Ruiz J, et al. Tratamiento de las infecciones fúngicas invasoras. Enferm Infecc Microbiol Clin. 2006;24:254-63.
47. Marco F, Danés C, Almela M, Jurado A, Mensa J, Puig de la Bellacasa J, et al. Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001). Diag Microbiol Infect Dis. 2003;46:259-64.
48. Mora-Duarte J, Betts R, Rotstein C, Lopes Colombo A, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020-9.
49. Ostrosky-Zeichner L, Oude Lashoff AML, Kullberg BJ, Rex JH. Voriconazole salvage treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis. 2003;22:651-5.
50. Oude Lashof AML, Donnelly JP, Meis JFGM, Meer JWM, Kullberg BJ. Duration of antifungal treatment and development of delayed complications in patients with candidaemia. Eur J Clin Microbiol Infect Dis. 2003;22:43-8.
51. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005;366:1435-42.
52. Cuenca-Estrella M, Rodríguez D, Almirante B, Morgan J, Planes AM, Almela M, et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005;55:194-99.
53. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother. 2004;48:693-715.
54. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 2003;36:1221-8.
55. Pacho J, Svoboda P, Jacobs F, Vandewoude K, Van der Hoven B, Spronk P, et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis. 2006;2:1404-13.